Mylan seeks entry into animal health via $29B bid for Perrigo

When Mylan ($MYL) offered to buy Perrigo ($PRGO) for $205 per share last Wednesday, the brewing $29 billion bid was hailed as the giant generics deal Wall Street has been anticipating. But this deal has an animal health angle too: If Mylan pulls it off, the acquisition will mark its entry into the veterinary market.

Perrigo markets several products in animal health, including the Sentry and Sergeant's Green line of flea-and-tick fighters. Perrigo acquired Sergeant's in 2012 for $285 million, also picking up a joint-health supplement for dogs and a calming collar for cats, among other products.

In 2013, Perrigo bought Velcera for $160 million, an acquisition which brought it the PetArmor line of flea-and-tick products.

But Mylan will have some work to do if it's to improve Perrigo's competitive position in animal health. On February 5, Perrigo announced that fiscal second-quarter sales in its animal division were disappointing. All told, the company suffered a $30 million decline in sales of existing products, most of which were in its contract-manufacturing and animal-health divisions.

Still, it's no surprise that Mylan is making an acquisition play that includes animal health products. Dealmaking in this industry has been on a roll this year, with Eli Lilly ($LLY) closing its $5.4 billion acquisition of Novartis ($NVS) Animal Health in January, for example, and AmeriSource Bergen ($ABC) handing over $2.5 billion for MWI Veterinary Supply shortly thereafter.

For Mylan, acquiring Perrigo could do much more than bring it into a lucrative new industry. Mylan has itself been the talk of buyout rumors for months, and days before its Perrigo bid it adopted a poison pill to fend off hostile takeovers. The Perrigo deal gives Mylan considerably more heft: The combined companies had $15.3 billion in 2014 sales--almost twice what Mylan pulled in on its own.

- here's Mylan's press release on the proposed deal

Suggested Articles

On New Year’s Day, Sanofi and Boehringer Ingelheim closed a $12.5 billion asset swap that had been in the works for a year, giving the closely held Germany-…

One of the priorities at France’s Ceva Santé Animale is to boost the company’s presence in the rapidly growing market for vaccines to prevent emerging diseases…

Jaguar Animal Health never caught fire on Wall Street after being spun out of Napo Pharmaceuticals in 2015. Its founders hope merging the company with its…